Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice OneMedNet Corp ONMD

OneMedNet Nasdaq/NYSE Compliance Notice

OneMedNet Corporation has regained compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from September 29, 2026, through October 12, 2026. Nasdaq has officially closed the matter, resolving the deficiency notice originally issued on April 14, 2026.

Counterparty
Nasdaq
8:00 AM ET 8-K
Contract Win Fermi Inc. FRMI

Fermi Wins $6.5B Contract from TensorWave

Fermi Inc. entered into a binding 15-year turnkey lease agreement with TensorWave for 222 MW of total power capacity at its Project Matador site. The contract is expected to generate $6.5 billion in revenue over the initial term and includes investment-grade credit support from AMD. Phased delivery of the capacity is scheduled to begin in Q4 2027 and complete in early 2028.

Value
$6.5B
Counterparty
TensorWave
Term
15 years
7:59 AM ET 8-K
Capital Raise Strive, Inc. ASST

Strive Capital Raise of $369M

Strive, Inc. announced the exercise of 273,493,909 traditional warrants between October 12 and October 13, 2026, resulting in the issuance of 13,674,703 shares of Class A common stock for gross proceeds of $369.2 million. Following these exercises, no warrants from the company's PIPE transaction remain outstanding. Additionally, the company disclosed the purchase of 2,822 bitcoin for approximately $235 million during the same period.

Value
$369M
7:57 AM ET 8-K
Leadership Change Akebia Therapeutics, Inc. AKBA

Akebia Therapeutics Leadership Change

Nicholas Grund, Senior Vice President and Chief Commercial Officer, notified Akebia Therapeutics of his resignation effective November 6, 2026, for personal reasons. Following his departure, Mr. Grund will provide consulting and advisory services to the company through April 30, 2027, under a newly established consulting agreement.

Term
through April 30, 2027
7:56 AM ET 8-K
Financial Results Fastenal Co FAST

Fastenal Financial Results

Fastenal Company reported Q3 2026 net sales of $2.46 billion, a 15.5% increase year-over-year, with diluted net income per share rising 19.8% to $0.35. The results were driven by strong daily sales growth, pricing actions, and share gains with larger customers, while operating margin improved 90 basis points to 21.5%.

Term
Q3 2026
7:56 AM ET 10-Q
Financial Results Ankam, Inc. ANKM

Ankam Q3 2026 Results: Net Loss of $113K, Loss Widens

Ankam, Inc. reported zero revenue for the three months ended August 31, 2026, and a net loss of $112,764, driven primarily by director fees and server expenses. The company's cash position significantly decreased to $8,321 from $131,710 at the end of 2025, resulting in a total stockholders' deficit of $760,617.

Key figure
Net loss $113K
7:52 AM ET 8-K
Clinical Trial Data Entrada Therapeutics, Inc. TRDA

Entrada Therapeutics Clinical Trial Data

Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.

7:50 AM ET 8-K
Loan & Debt Cipher Digital Inc. CIFR

Cipher Digital $850M Debt Financing

Cipher Digital Inc. priced a private offering of $850 million in 0.00% convertible senior notes due 2032, with an additional $150 million overallotment option for purchasers. Concurrently, the company is exchanging $165.9 million of its existing 1.75% convertible senior notes due 2030 for approximately 40.7 million shares of common stock.

Value
$850M
Term
through 2032
7:45 AM ET 8-K
Nasdaq/NYSE Compliance Notice Brightline Interactive, Inc. BTLN

Brightline Interactive Nasdaq/NYSE Compliance Notice

Brightline Interactive regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days. The company achieved this by implementing a 1-for-8 reverse stock split effective September 28, 2026, following a prior delisting notice. The matter is now closed and the company's stock continues to trade on the Nasdaq Capital Market under the symbol BTLN.

Counterparty
The Nasdaq Stock Market LLC
7:39 AM ET 8-K
Financial Results Morgan Stanley MS

Morgan Stanley Financial Results

Morgan Stanley reported third-quarter 2026 net revenues of $20.3 billion and net income of $4.9 billion, or $3.03 per diluted share. The results were driven by record revenues in Wealth Management and strong performance in Institutional Securities, particularly within the Equity franchise.

Term
Q3 2026

“Morgan Stanley reported another strong quarter with net revenues of $20.3 billion, EPS of $3.03 and a ROTCE of 22.6%. The Integrated Firm is connecting the full breadth of Morgan Stanley to deliver differentiated solutions and advice for our clients. Institutional Securities benefited from global strength, led by our Equity franchise, and Wealth Management reported record revenues and added $232 billion in net new assets and $80 billion in fee-based flows. Across Wealth and Investment Management, total client assets grew to $10.5 trillion, demonstrating the scale of our platform and the strength of our franchise. We continue to invest for growth while delivering strong returns for shareholders.”

Ted Pick, Chairman and Chief Executive Officer
7:33 AM ET 8-K
Divestiture Faraday Future Intelligent Electric Inc. FFAI

Faraday Future Intelligent Electric Divestiture to FF EAI Robotics Ecosystem Inc. for $200M

Faraday Future Intelligent Electric Inc. (FFAI) entered into a definitive agreement to sell its robotics business to FF EAI Robotics Ecosystem Inc. (FFR) for an aggregate consideration of approximately $200 million. The transaction is an all-stock deal where FFAI will receive FFR common and preferred stock, resulting in FFAI holding a 65.7% controlling interest in FFR upon closing. The deal allows FFAI to monetize its robotics assets while maintaining majority control of the newly pure-play robotics entity.

Value
$200M
Counterparty
FF EAI Robotics Ecosystem Inc. (FFR)
7:32 AM ET 8-K
M&A Deal FF EAI Robotics Ecosystem Inc. FFR

FF EAI Robotics Ecosystem Signs $200M M&A Deal with Faraday Future Intelligent Electric Inc.

FF EAI Robotics Ecosystem Inc. entered into a definitive transaction agreement to acquire the robotics business of its majority stockholder, Faraday Future Intelligent Electric Inc. (FFAI), for approximately $200 million. The all-stock deal involves the issuance of common and preferred shares at a valuation of $2.246 per share, making the company a pure-play humanoid and bionic robotics entity. The transaction is expected to close by the end of October 2026, resulting in FFAI holding approximately 65.7% of the combined company.

Value
$200M
Counterparty
Faraday Future Intelligent Electric Inc.
7:31 AM ET 8-K
Financial Results State Street Corp STT

State Street Financial Results

State Street reported third-quarter 2026 net income of $1.09 billion on total revenue of $4.0 billion, representing a 13% year-over-year increase. The results were driven by record quarterly servicing and management fees and record FX client volumes, resulting in diluted EPS of $3.69. The company also announced the election of Alexander Vollert as an independent director and the planned redemption of $500 million in senior notes due 2027.

Term
Q3 2026

“The strength of our third-quarter results demonstrates continued momentum and disciplined execution across our global franchises. We generated record quarterly Servicing and Management fees as well as record FX client volumes, reflecting the strength of our client relationships and the breadth of our capabilities. This performance drove our eleventh consecutive quarter of year-over-year positive operating leverage, excluding notable items, resulting in pre-tax margin expansion to approximately 35%.”

Ron O’Hanley, Chairman and Chief Executive Officer

“We enter the final quarter of the year with strong momentum, a clear strategy, and confidence in our ability to deliver against our medium-term targets while continuing to create long-term value for shareholders.”

Ron O’Hanley, Chairman and Chief Executive Officer
7:30 AM ET 8-K
Loan & Debt Karyopharm Therapeutics Inc. KPTIQ

Karyopharm Therapeutics Debt Financing Update

Karyopharm Therapeutics Inc. has extended its existing forbearance period under a Forbearance Agreement and Limited Waiver to Indentures. The expiration date of the forbearance period was moved from October 15, 2026, to October 22, 2026, providing the company additional time to address its debt obligations.

7:21 AM ET 8-K
Licensing Deal Aquestive Therapeutics, Inc. AQST

Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M

Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.

Value
$57.5M
Counterparty
Eton Pharmaceuticals, Inc.
Term
20 years
7:15 AM ET 8-K
M&A Deal Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.

Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.

Value
$10M
Counterparty
Aquestive Therapeutics, Inc.
Term
20 years
7:10 AM ET 8-K
Financial Results Sono Tek Corp SOTK

Sono Tek Financial Results

Sono-Tek reported fiscal second quarter 2027 results with net sales of $5.23 million and net income of $366,000. For the first half of the fiscal year, revenue increased 6% to $10.89 million, driven by a 289% surge in medical market sales. The company reiterated its full-year guidance for flat to modest revenue growth due to the timing of large orders.

Term
Q2 2027

“Fiscal 2027 is progressing well, with solid first-half revenue growth, meaningful gross margin expansion and strong improvement in operating profitability. These results reflect disciplined execution across our operations and continued progress with our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.”

Steve Harshbarger, President and Chief Executive Officer
7:08 AM ET 8-K
Court & Legal Update Xeris Biopharma Holdings, Inc. XERS

Xeris Biopharma Holdings Court & Legal Update

Xeris Biopharma Holdings filed patent infringement lawsuits in the U.S. District Court for the District of New Jersey against several pharmaceutical companies regarding its KEVEYIS® (dichlorphenamide) product. The lawsuits allege infringement of U.S. Patent No. 12,758,502 and seek injunctive relief and monetary damages to prevent the defendants from marketing generic versions of the drug.

Counterparty
Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
7:05 AM ET 8-K
Dividend Entegris Inc ENTG

Entegris Dividend

Entegris, Inc. announced that its board of directors has declared a quarterly cash dividend of $0.10 per share. The dividend is payable on November 18, 2026, to shareholders of record as of the close of business on October 28, 2026.

7:01 AM ET 8-K
Leadership Change Compass, Inc. COMP

Compass Leadership Change

Compass, Inc. announced the appointment of former Google executive Sissie L. Hsiao to its Board of Directors, effective October 14, 2026. This follows the resignation of Lead Independent Director Charles E. Phillips, Jr., who stepped down to focus on other commitments. In related moves, Frank Martell was appointed Lead Independent Director and Steven Sordello was named Chairperson of the Nominating and Corporate Governance Committee.

7:01 AM ET 8-K
Executive Compensation XTI Aerospace, Inc. XTIA

XTI Aerospace Executive Compensation

XTI Aerospace, Inc. appointed Dr. Allan Evans as a Class I director and Chairman of the Board, effective October 14, 2026. Dr. Evans will receive an annual cash retainer of $50,000 and an annual grant of stock options with a fair market value equal to his annual cash retainer. Jonathan G. Ornstein, who previously served as Interim Chairman, was designated as Vice Chairman in connection with the appointment.

7:01 AM ET 8-K
Court & Legal Update United Therapeutics Corp UTHR

United Therapeutics Court & Legal Update

United Therapeutics entered into a comprehensive settlement agreement with Liquidia Technologies to resolve multiple patent infringement and trade secret lawsuits. Liquidia will pay United Therapeutics $330.4 million in damages and has agreed to remove the PH-ILD indication from its Yutrepia product labeling, while United Therapeutics will pay Liquidia $10.0 million to resolve separate infringement claims.

Counterparty
Liquidia Technologies, Inc.
7:00 AM ET 8-K
Business Update Range Resources Corp RRC

Range Resources Business Update

Range Resources Corporation provided preliminary estimates for its derivative settlements for the third quarter ended September 30, 2026. The company expects to report a total gain on derivatives of $58.1 million and total net cash receipts on derivative settlements of approximately $51.9 million.

Term
Q3 2026
6:45 AM ET 8-K
Financial Results Bank of America Corp BAC

Bank of America Financial Results

Bank of America reported Q3 2026 net income of $6.9 billion, or $0.91 per share, on revenue of $30.0 billion. Results were impacted by a $1.2 billion regulatory settlement charge, with adjusted EPS coming in at $1.08. The quarter saw 8% year-over-year growth in net interest income and strong organic growth in consumer deposits and wealth management flows.

Term
Q3 2026

“The team delivered organic growth, deepening client relationships and adding new ones. While investment banking and sales and trading revenues were lower, commercial lending grew in every client segment. Our momentum, reflected in growth in client deposits, wealth flows and consumer activity, supported solid earnings, balance-sheet growth and long-term shareholder value.”

Brian Moynihan, Chair and CEO

“Our disciplined investments in AI are helping teammates serve clients better, work faster and manage risk more effectively. With more than 200,000 teammates using AI tools and 300-plus approved use cases across the company, we are turning our scale into a competitive advantage.”

Brian Moynihan, Chair and CEO
6:44 AM ET 8-K
Investor Presentation Accenture plc ACN

Accenture Investor Presentation

Accenture hosted its 2026 Investor Day, providing a review of FY26 performance and outlining strategic financial ambitions through FY29. The company targets mid-single digit revenue growth in FY27-FY28 and mid-to-high single digit growth in FY29, alongside 10-30 bps of annual operating margin expansion.

6:40 AM ET 8-K
Other 8-K Filing National Fuel Gas Co NFG

National Fuel Gas Other 8-K Filing

National Fuel Gas Company announced a plan to separate into two independent, publicly traded companies through a tax-free spin-off of its Integrated Upstream and Gathering (IUG) business. The separation, expected to complete in the second half of 2027, will create a 100% rate-regulated natural gas utility and pipeline company and a standalone Appalachian upstream natural gas entity.

6:40 AM ET 8-K
Financial Results BlackRock, Inc. BLK

BlackRock Financial Results

BlackRock reported third quarter 2026 results with $205 billion in quarterly net inflows and a record $15.5 trillion in assets under management. Revenue increased 19% year-over-year, driven by organic base fee growth, higher performance fees, and momentum in technology services like Aladdin. Adjusted diluted EPS rose 38% to $15.93, reflecting strong operating performance and higher nonoperating income.

Term
Q3 2026

“BlackRock's results demonstrate the value of our integrated platform, as clients increasingly choose us as a partner across investing, financing, and technology. That client trust is translating into higher earnings power, with shareholders benefiting from a more than 35% increase in adjusted earnings per share year-over-year, a 47.8% adjusted operating margin, and 11% annualized organic base fee growth in the third quarter.”

Laurence D. Fink, Chairman and CEO

“BlackRock is in a differentiated position as both a trusted advisor and destination for global client capital. That position is powering organic growth and value for our shareholders. We’re entering our seasonally strongest fourth quarter with accelerating momentum, and a broad pipeline spanning whole portfolio, private markets, retirement, and our international platforms.”

Laurence D. Fink, Chairman and CEO
6:36 AM ET 8-K
Other 8-K Filing Quoin Pharmaceuticals Ltd. QNRX

Quoin Pharmaceuticals Other 8-K Filing

Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides 10 years of market exclusivity in Europe upon potential marketing authorization and follows similar regulatory milestones in the US and Japan. The company remains on track to initiate the first-ever formal clinical study for Peeling Skin Syndrome before the end of 2026.

Counterparty
European Medicines Agency
6:21 AM ET Form 4
Insider Buying Baozun Inc. BZUN

Baozun CEO Wenbin Qiu Buys $40.2K of Stock

Wenbin Qiu, CEO, bought 11,800 shares of Baozun Inc. at $3.34 to $3.47 a share (average $3.40) in 2 transactions, worth $40.2K in total between Oct 12, 2026 and Oct 13, 2026. Shares held after the trade: 1,678,572 (+0.3%).

Value
$40.2K
Shares
11,800
Average price
$3.40
Role
CEO
Holding change
+0.3%
Trade date
Oct 12, 2026 to Oct 13, 2026
6:08 AM ET 8-K
Leadership Change Verastem, Inc. VSTM

Verastem Leadership Change

Verastem Oncology announced that Daniel W. Paterson will retire as President and CEO effective January 1, 2027, and will be succeeded by Michael P. Bailey. Mr. Paterson will remain on the Board of Directors and serve as an advisor, while Mr. Bailey, an existing director with over 30 years of industry experience, will lead the company's next phase of commercial growth.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.